Bioactivity
Mechanism is payload-independent: farletuzumab is a naked anti-FRalpha mAb acting via ADCC, CDC, induction of autophagy, and inhibition of FRalpha-Lyn kinase growth signaling; it does not block folate binding/transport. No cytotoxic-payload IC50 applies.